Home
Resources
Publications
5-Methoxypsoralen (Bergapten) in Photochemotherapy of Psoriasis

5-Methoxypsoralen (Bergapten) in Photochemotherapy of Psoriasis

H Hönigsmann, E Jaschke, F Gschnait, W Brenner, P Fritsch, K Wolff

Br J Dermatol. 1979 Oct;101(4):369-78.

PMID: 508604

Abstract:

5-Methoxypsoralen (5-MOP, Bergapten) was evaluated as a potential photosensitizing drug in oral photochemotherapy of psoriasis. Treatment results indicate that (1) 5-MOP is as effective as, and in high doses more effective than, 8-methoxypsoralen in clearing psoriatic lesions; (2) therapeutic doses of 5-MOP do not lead to erythema; the acute side-effects of 8-MOP PUVA therapy--erythema, blistering, pruritus--are thus avoided; (3) even high doses of 5-MOP are not followed by nausea. 5-MOP PUVA therapy thus represents a real alternative to 8-MOP PUVA, its advantages over 8-MOP PUVA being greater safety and patient acceptance.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP484208-B	5-Methoxypsoralen		484-20-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: